Emil Kuriakose, MD

Chief Medical Officer, Oncology at Terns Pharmaceuticals
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
Greater Houston

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
You need to have a working account to view this content.

Experience

    • United States
    • Pharmaceutical Manufacturing
    • 1 - 100 Employee
    • Chief Medical Officer, Oncology
      • Mar 2023 - Present

      Foster City, California, United States

    • United States
    • Pharmaceutical Manufacturing
    • 1 - 100 Employee
    • Chief Medical Officer
      • Nov 2021 - Mar 2023

    • Vice President, Head of Clinical Development
      • Jan 2021 - Nov 2021

    • Vice President, Clinical Development
      • Feb 2020 - Nov 2021

      South San Francisco, California

    • Senior Medical Director
      • Oct 2017 - Feb 2020

      San Francisco Bay Area

    • Switzerland
    • Pharmaceutical Manufacturing
    • 700 & Above Employee
    • Global Clinical Program Lead
      • Jan 2016 - Sep 2017

      East Hanover, NJ -Global head of early development for MDM2 inhibitor (targeted therapy) and adenosine inhibitor (I-O) programs in solid and hematologic malignancies -Responsible for creating and executing clinical development of new oncology agents from the candidate selection process (CSP) to clinical proof of concept (PoC) stage, encompassing strategy for path to registration -Responsible for integrated development plan including design and execution of phase 1 and 2 clinical trials of novel compounds… Show more -Global head of early development for MDM2 inhibitor (targeted therapy) and adenosine inhibitor (I-O) programs in solid and hematologic malignancies -Responsible for creating and executing clinical development of new oncology agents from the candidate selection process (CSP) to clinical proof of concept (PoC) stage, encompassing strategy for path to registration -Responsible for integrated development plan including design and execution of phase 1 and 2 clinical trials of novel compounds in oncology and immuno-oncology portfolio -Lead multi-disciplinary team comprised of clinical pharmacology, pre-clinical biology, pre-clinical safety, correlative biomarkers, technical research and development, biostatistics and data management, global clinical operations, global regulatory affairs, and early commercial strategy -Ensure ethical and efficient conduct of early phase clinical trials in compliance with Good Clinical Practice guidelines Show less

    • Switzerland
    • Pharmaceutical Manufacturing
    • 700 & Above Employee
    • Medical Director
      • Jul 2013 - Jan 2016

      United States, East Hanover, NJ -Oversaw clinical development, strategy, and medical affairs program for Farydak (HDACi), Sonidegib (Hh inhibitor), and Afuresertib (AKTi) in the US. -Led cross-functional medical product teams consisting of clinical operations, field medical, managed markets, HEOR, drug regulatory, medical information, and scientific communications. -Developed LCM plan and strategy for compounds by disease state, working with key internal stakeholders. -Designed and executed phase 1 through 4 clinical… Show more -Oversaw clinical development, strategy, and medical affairs program for Farydak (HDACi), Sonidegib (Hh inhibitor), and Afuresertib (AKTi) in the US. -Led cross-functional medical product teams consisting of clinical operations, field medical, managed markets, HEOR, drug regulatory, medical information, and scientific communications. -Developed LCM plan and strategy for compounds by disease state, working with key internal stakeholders. -Designed and executed phase 1 through 4 clinical trials aligned with compound LCM strategy. -Oversaw over 75 medical affairs studies conducted in collaboration with third-party investigators. Show less

    • United States
    • Hospitals and Health Care
    • 700 & Above Employee
    • Research Fellow
      • Jun 2011 - Jun 2013

      Research fellow in The Malcolm Moore Lab

    • United States
    • Hospitals and Health Care
    • 700 & Above Employee
    • Hematology/Oncology Fellow
      • Jul 2010 - Jun 2013

      Weill Cornell Medical College -Awarded The Johns Family Foundation Clinical Fellowship in hematology/oncology, -specialized in clinical and translational research in myeloproliferative neoplasms.

    • Attending Hospitalist
      • Jun 2009 - Jun 2010

    • United States
    • Hospitals and Health Care
    • 700 & Above Employee
    • Resident physician
      • Jul 2006 - Jun 2009

Education

  • New York University
    BS, Neural Science
  • SUNY Stony Brook Medical Center
    Doctor of Medicine (MD)

Community

You need to have a working account to view this content. Click here to join now